Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mubritinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 known ✓ | P04626 | 20/20 | 0.98 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mubritinib SCHEMBL6758911 | 1.00 | ERBB2 (0.98) | ERBB2MINK1 | |
| Mubritinib SCHEMBL94943 | 0.99 | ERBB2 (1.00) | ERBB2MINK1 | |
| Mubritinib SCHEMBL571874 | 0.99 | ERBB2 (1.00) | ERBB2MINK1 | |
| SCHEMBL6579812 | 0.97 | ERBB2 (0.95) | ERBB2MINK1 | |
| SCHEMBL6579814 | 0.97 | ERBB2 (0.95) | ERBB2MINK1 | |
| Mubritinib SCHEMBL6758898 | 0.95 | ERBB2 (0.91) | ERBB2MINK1 | |
| Mubritinib SCHEMBL6758904 | 0.95 | ERBB2 (0.91) | ERBB2MINK1 | |
| Mubritinib SCHEMBL6760647 | 0.93 | ERBB2 (0.88) | ERBB2MINK1 | |
| Mubritinib SCHEMBL6760644 | 0.93 | ERBB2 (0.88) | ERBB2MINK1 | |
| Hydrochloric Acid SCHEMBL5521540 | 0.92 | ERBB2 (0.83) | ERBB2MINK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040106803-A1 | Production method of 1-substituted-1,2,3-triazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-06-03 | — | — | US | disclosed |
| US-6743924-B2 | EFFICIENT, HIGH YEILD SYNTHESIS OF TYROSINE KINASE INHIBITORS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2004-06-01 | — | — | US | disclosed |
| EP-1310491-A1 | METHOD FOR PRODUCING 1-SUBSTITUTED-1,2,3-TRIAZOLE DERIVATIVE | Takeda Chemical Industries, Ltd. (JP) | 2003-05-14 | — | — | EP | disclosed |
| US-20030069419-A1 | Method for producing 1-substituted-1,2,3- triazole derivative | TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2003-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106803-A1 | Production method of 1-substituted-1,2,3-triazole derivatives | ABL1, ROS1, ADH1A | ERBB2 78/4885MINK1 359/4885 |
| US-20030069419-A1 | Method for producing 1-substituted-1,2,3- triazole derivative | ABL1, YES1, MAP3K1 | ERBB2 77/4885MINK1 330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.